scholarly article | Q13442814 |
P50 | author | A-L Huber | Q83924619 |
P2093 | author name string | Zhizhong Li | |
Katja A Lamia | |||
Alanna B Chan | |||
Anna Kriebs | |||
Christian M Metallo | |||
Emma Henriksson | |||
Madelena Nguyen | |||
Martina Wallace | |||
Sabine D Jordan | |||
Stephanie J Papp | |||
P2860 | cites work | Fbw7 and Usp28 regulate myc protein stability in response to DNA damage | Q24293749 |
Myc-Nick: A Cytoplasmic Cleavage Product of Myc that Promotes α-Tubulin Acetylation and Cell Differentiation | Q24294609 | ||
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex | Q24294734 | ||
Coupling of human circadian and cell cycles by the timeless protein | Q24299164 | ||
SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins | Q24304073 | ||
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase | Q24304122 | ||
Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm | Q24321406 | ||
FBXL21 Regulates Oscillation of the Circadian Clock through Ubiquitination and Stabilization of Cryptochromes | Q24321496 | ||
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7 | Q24337643 | ||
Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase | Q24337721 | ||
The human Tim/Tipin complex coordinates an Intra-S checkpoint response to UV that slows replication fork displacement | Q24683336 | ||
Molecular architecture of the mammalian circadian clock | Q27004052 | ||
Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases | Q27644446 | ||
Functional motifs in the (6-4) photolyase crystal structure make a comparative framework for DNA repair photolyases and clock cryptochromes | Q27654626 | ||
SCFFBXL3 ubiquitin ligase targets cryptochromes at their cofactor pocket | Q27676853 | ||
Crystal structure of mammalian cryptochrome in complex with a small molecule competitor of its ubiquitin ligase | Q27680111 | ||
UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo | Q28206180 | ||
Coordinated transcription of key pathways in the mouse by the circadian clock | Q28217978 | ||
Divorcing ARF and p53: an unsettled case | Q28258356 | ||
Circadian transcription of the cholesterol 7 alpha hydroxylase gene may involve the liver-enriched bZIP protein DBP | Q28264406 | ||
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells | Q28275988 | ||
The cost of circadian desynchrony: Evidence, insights and open questions | Q28385845 | ||
The Circadian Clock in Cancer Development and Therapy | Q28390451 | ||
Circadian mutant Overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression | Q28509189 | ||
Delay in feedback repression by cryptochrome 1 is required for circadian clock function | Q28512076 | ||
The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period | Q28594339 | ||
Extensive and divergent circadian gene expression in liver and heart | Q29615206 | ||
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation | Q29616127 | ||
Transcriptional architecture and chromatin landscape of the core circadian clock in mammals | Q29616252 | ||
Resetting of circadian time in peripheral tissues by glucocorticoid signaling | Q29616364 | ||
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia | Q29616650 | ||
Inference of cell cycle-dependent proteolysis by laser scanning cytometry | Q33424132 | ||
Tipin-replication protein A interaction mediates Chk1 phosphorylation by ATR in response to genotoxic stress | Q33541382 | ||
Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice | Q33601559 | ||
Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. | Q33890400 | ||
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. | Q33948902 | ||
Control of skin cancer by the circadian rhythm | Q34057127 | ||
Transcriptional amplification in tumor cells with elevated c-Myc. | Q34302542 | ||
The circadian factor Period 2 modulates p53 stability and transcriptional activity in unstressed cells | Q34504101 | ||
The Molecular Signatures Database (MSigDB) hallmark gene set collection | Q34509167 | ||
JETLAG resets the Drosophila circadian clock by promoting light-induced degradation of TIMELESS. | Q34541185 | ||
Regulation of substrate utilization by the mitochondrial pyruvate carrier | Q34710980 | ||
Modelling Myc inhibition as a cancer therapy | Q34811008 | ||
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation | Q34835596 | ||
Association of the circadian factor Period 2 to p53 influences p53's function in DNA-damage signaling | Q34960791 | ||
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis | Q35081562 | ||
Regulation of apoptosis by the circadian clock through NF-kappaB signaling | Q35123146 | ||
DNA damage shifts circadian clock time via Hausp-dependent Cry1 stabilization | Q35156678 | ||
Identification of a Novel Cryptochrome Differentiating Domain Required for Feedback Repression in Circadian Clock Function | Q36122122 | ||
Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis | Q36122673 | ||
Histone monoubiquitination by Clock-Bmal1 complex marks Per1 and Per2 genes for circadian feedback. | Q36144279 | ||
CLOCK deubiquitylation by USP8 inhibits CLK/CYC transcription in Drosophila | Q36421773 | ||
Tumor suppression by the mammalian Period genes | Q36441046 | ||
Circadian clocks, epigenetics, and cancer | Q36520424 | ||
DNA damage-specific control of cell death by cryptochrome in p53-mutant ras-transformed cells | Q36545099 | ||
Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. | Q36569870 | ||
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice | Q36708046 | ||
MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. | Q36760018 | ||
Tumor suppression and circadian function | Q36895164 | ||
Loss of cryptochrome reduces cancer risk in p53 mutant mice | Q37081282 | ||
SREBP1c-CRY1 signalling represses hepatic glucose production by promoting FOXO1 degradation during refeeding | Q37099495 | ||
Substrate binding promotes formation of the Skp1-Cul1-Fbxl3 (SCF(Fbxl3)) protein complex | Q37289330 | ||
Proteolytic Control of the Oncoprotein Transcription Factor Myc | Q37894329 | ||
The circadian clock and cell cycle: interconnected biological circuits | Q38130824 | ||
MYC degradation | Q38193043 | ||
Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. | Q38305728 | ||
Carcinogenicity of shift-work, painting, and fire-fighting | Q38459347 | ||
Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. | Q38973733 | ||
Circadian Dbp transcription relies on highly dynamic BMAL1-CLOCK interaction with E boxes and requires the proteasome | Q39278235 | ||
Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization | Q40625392 | ||
Chronically Alternating Light Cycles Increase Breast Cancer Risk in Mice. | Q40713268 | ||
Circadian Rhythm Disruption Promotes Lung Tumorigenesis | Q41921459 | ||
Ink4‐Arf locus in cancer and aging | Q42153635 | ||
Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses | Q48347156 | ||
The circadian molecular clock creates epidermal stem cell heterogeneity | Q51847597 | ||
GSEA-P: a desktop application for Gene Set Enrichment Analysis | Q51909999 | ||
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas | Q55670934 | ||
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice | Q57338722 | ||
Comprehensive identification of substrates for F-box proteins by differential proteomics analysis | Q83959951 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 774-789 | |
P577 | publication date | 2016-10-31 | |
P1433 | published in | Molecular Cell | Q3319468 |
P1476 | title | CRY2 and FBXL3 Cooperatively Degrade c-MYC. | |
P478 | volume | 64 |
Q94560972 | A Systems Biology Approach Identifies Hidden Regulatory Connections Between the Circadian and Cell-Cycle Checkpoints |
Q38690893 | CRY1/2 Selectively Repress PPARδ and Limit Exercise Capacity. |
Q99550813 | Cancer in the Fourth Dimension: What Is the Impact of Circadian Disruption? |
Q33624949 | Circadian Clock, Cell Division, and Cancer: From Molecules to Organism |
Q92471718 | Circadian Clocks and Cancer: Timekeeping Governs Cellular Metabolism |
Q52731213 | Cry2 Is Critical for Circadian Regulation of Myogenic Differentiation by Bclaf1-Mediated mRNA Stabilization of Cyclin D1 and Tmem176b |
Q90091516 | Cryptochromes modulate E2F family transcription factors |
Q33809578 | Desynchronization of Circadian Clocks in Cancer: A Metabolic and Epigenetic Connection. |
Q99566804 | Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma |
Q90746433 | F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects |
Q64080120 | G1/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment |
Q58572607 | Human and Murine Evidence for Mechanisms Driving Autoimmune Photosensitivity |
Q97419063 | Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas |
Q91562163 | Integrative Analysis of NSCLC Identifies LINC01234 as an Oncogenic lncRNA that Interacts with HNRNPA2B1 and Regulates miR-106b Biogenesis |
Q92675538 | Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment |
Q90777135 | Isoform-selective regulation of mammalian cryptochromes |
Q60310158 | JMJD5 links CRY1 function and proteasomal degradation |
Q132730853 | Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality |
Q99207689 | Metabolic rivalry: circadian homeostasis and tumorigenesis |
Q91452385 | Molecular mechanisms and physiological importance of circadian rhythms |
Q90482809 | Molecular principles of metastasis: a hallmark of cancer revisited |
Q64998192 | Non-transcriptional processes in circadian rhythm generation. |
Q58098943 | Opposite Carcinogenic Effects of Circadian Clock Gene BMAL1 |
Q93143949 | Phosphorylation of CRY1 Serine 71 Alters Voluntary Activity but Not Circadian Rhythms In Vivo |
Q33573675 | Systems Chronotherapeutics |
Q52727400 | The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. |
Q38620481 | The Liver Circadian Clock Modulates Biochemical and Physiological Responses to Metformin |
Q60907652 | The circadian E3 ligase complex SCF targets TLK2 |
Q64969261 | The emerging link between cancer, metabolism, and circadian rhythms. |
Q52577062 | The endogenous circadian clock programs animals to eat at certain times of the 24-hour day: What if we ignore the clock? |
Q92665751 | The role of aurora A and polo-like kinases in high-risk lymphomas |
Q64974084 | The role of circadian clock genes in tumors. |
Q47130821 | Ticking time bombs: connections between circadian clocks and cancer. |
Q90642449 | Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases |
Q48350201 | WNT Takes Two to Tango: Molecular Links between the Circadian Clock and the Cell Cycle in Adult Stem Cells. |
Q91940275 | Writing and erasing MYC ubiquitination and SUMOylation |
Q38657851 | miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer |
Search more.